A new cancer vaccine involving an immunotherapy drug and a chemical that boosts its efficacy has just shown a 100% success rate in treating melanoma in mice, according to a new study.

The news is promising, with researchers even being able to show their new therapy can fight cancer recurrence down the track, which could mean fewer relapses in the future.

Dale Boger is one of the researchers from the Scripps Research Institute in California. “This co-therapy produced a complete response – a curative response – in the treatment of melanoma.”